Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma

Bone Marrow Transplantation volume 54, pages 625–628 (2019)Cite this article

Subjects

We previously accessed the safety and efficacy of lomustine in combination with etoposide, cytarabine, and melphalan (LEAM) for 4 days, in a Phase 1 study with 3 + 3 design, defining the maximum tolerated dose (MTD) of lomustine at 300 mg/m2 [1].

This study was a single arm, phase 1/2 multicenter (three Brazilian centers), dose-escalation for investigating lomustine administered in combination with etoposide, aracytin, and melphalan as conditioning regimen in relapsed/refractory non Hodgkin lymphoma and Hodgkin lymphoma for auto-hematopoietic stem cell transplantation (HSCT). The local Ethical Committee, number 139-420-2011, CAAE 0102.0.420.000-11, approved the study. Phase 1 primary objective was to identify the MTD of lomustine. Phase 2 objective was to evaluate the overall survival (OS) and progression-free survival (PFS) of LEAM regimen. Secondarily, we also assessed the safety and tolerability of this regimen in comparison with historical control series of patients submitted to auto-HSCT with CBV as conditioning in our institution.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Santos KB, Pereira J, Atalla A, Costa LucianoJ, Neto AEH. The use of lomustine in combination with etoposide, cytarabine and melphalan in a brief conditioning for auto-HSCT in patients with lymphoma: the optimal dose. Bone Marrow Transplant. 2014;49:1239–40.

    Article  Google Scholar 

  2. Damaj G, Cornillon J, Bouabdallah K, Gressin R, Vigouroux S, Gastinne T, et al. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Bone Marrow Transplant. 2017;52:941–9.

    Article  CAS  Google Scholar 

  3. Chao NJ, et al. A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer . 1995;75:1354–9.

    Article  CAS  Google Scholar 

  4. Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;10:163–7.

    Article  Google Scholar 

  5. Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin’s disease. Biol Blood Marrow Transplant. 2001;7:552–60.

    Article  CAS  Google Scholar 

  6. Sharma A, Kayal S, Iqbal S, Malik PS, Raina V. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. +. 2013;2:489.

    PubMed  PubMed Central  Google Scholar 

  7. Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;41:613–9.

    Article  CAS  Google Scholar 

  8. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008;87:43–8.

    Article  CAS  Google Scholar 

  9. Kumar L, Ganessan P, Ghosh I, Panda D, Gogia A, Mandhania S. Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: complications and outcome. Natl Med J India. 2010;23:330–5.

    PubMed  Google Scholar 

  10. Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation (AutoHCT). Biol Blood Marrow Transplant. 2015;21:1046–53.

    Article  Google Scholar 

  11. Youwu SHI, Peng LIU, Shengyu ZHOU, Jianliang YANG, Xiaohong HAN, Xiaohui HE. et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: efficacy and toxicity. Asia Pac J Clin Oncol. 2017;13:e423–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology and Bone Marrow Transplantation Center of University Hospital, Federal University of Juiz de Fora, Rua Catulo Breviglieri, s/n, Bairro Santa Catarina, Juiz de Fora, Minas Gerais, 36036-110, Brazil

    Kelli Borges dos Santos

  2. Bone Marrow Transplantation and Cell Therapy Program of UAB-CCC, Alabama, Birmingham, 36036-110, USA

    Luciano José Megale Costa

  3. Cardiology Institute of Distrito Federal, Brasilia, Distrito Federal, 36036-110, Brazil

    Gustavo Bettarello

  4. University Hospital, Federal University of Juiz de Fora, Rua Catulo Breviglieri, s/n, Bairro Santa Catarina, Juiz de Fora, Minas Gerais, 36036-110, Brazil

    Marcus da Matta Abreu

  5. Bone Marrow Transplantation Center of University Hospital, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, 36036-110, Brazil

    Graziela Toledo Costa Mayrink

  6. Transfusion Agency of the University Hospital at the Federal University of Juiz de Fora, Rua Catulo Breviglieri, s/n, Bairro Santa Catarina, Juiz de Fora, Minas Gerais, 36036-110, Brazil

    Mariza Aparecida Mota

  7. Department of Statistics of the Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, 36036-110, Brazil

    Luiz Cláudio Ribeiro

  8. Laboratory of Immunopathology, Hematology Service, Cental Institute of Cancer of Hospital das Clínicas, FM-USP, São Paulo, Brazil

    Juliana Pereira

  9. Bone Marrow Transplantation Center of University Hospital, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, 36036-110, Brazil

    Abrahão Elias Hallack Neto

Authors
  1. Kelli Borges dos Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luciano José Megale Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gustavo Bettarello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcus da Matta Abreu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Graziela Toledo Costa Mayrink
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mariza Aparecida Mota
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luiz Cláudio Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Juliana Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Abrahão Elias Hallack Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelli Borges dos Santos.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

dos Santos, K.B., Costa, L.J.M., Bettarello, G. et al. LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma. Bone Marrow Transplant 54, 625–628 (2019). https://doi.org/10.1038/s41409-018-0349-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0349-4

This article is cited by

Search

Advanced search

Quick links